Stimulus properties of venlafaxine in a conditioned taste aversion procedure

European Journal of Pharmacology

Volumn 596, Issue 1-3, 2008, Pages 102-106

  Kayir, Hakan ^a   Alici, Tevfik ^a,b   Göktalay, Gökhan ^a,c   Yildirim, Murat ^a   Ulusoy, Gökhan K ^a   Ceyhan, Mert ^a   Celik, Turgay ^a   Uzbay, Tayfun I ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b MUGLA SITKI KOCMAN UNIVERSITY   (Turkey)

^c ULUDAG UNIVERSITY   (Turkey)

Author keywords

(Mice); Antidepressant; Conditioned taste aversion; Escitalopram; Fluoxetine; l NAME; Reboxetine; Tianeptine; Venlafaxine

Indexed keywords

ESCITALOPRAM; FLUOXETINE; GLUCOSE; N(G) NITROARGININE METHYL ESTER; NORADRENALIN; REBOXETINE; SEROTONIN; TIANEPTINE; VENLAFAXINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG SUBSTITUTION; FLUID INTAKE; GLUCOSE INTAKE; INSTRUMENTAL CONDITIONING; MALE; MOUSE; NEUROTRANSMITTER UPTAKE; NONHUMAN; PRIORITY JOURNAL; STIMULUS RESPONSE; SWISS WEBSTER MOUSE; TASTE AVERSION;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS; AVOIDANCE LEARNING; CONDITIONING (PSYCHOLOGY); CYCLOHEXANOLS; MALE; MICE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SEROTONIN UPTAKE INHIBITORS; TASTE;

EID: 53049098693     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.08.015     Document Type: Article

References (31)

1. Alici T., Kayir H., Aygoren M.O., Saglam E., and Uzbay I.T. Discriminative stimulus properties of tianeptine. Psychopharmacology 183 (2006) 446-451
2. Andrews J.M., Ninan P.T., and Nemeroff C.B. Venlafaxine: a novel antidepressant that has a dual mechanism of action. Depression 4 (1996) 48-56
3. Berendsen H.H., and Broekkamp C.L.E. Comparison of stimulus properties of fluoxetine and 5-HT receptor agonists in a conditioned taste aversion procedure. Eur. J. Pharmacol. 253 (1994) 83-89
4. 1A agonistic effects of the new antidepressant mirtazapine. Psychopharmacology 133 (1997) 275-282
5. 1A receptor agonist 8-OH-DPAT. Psychopharmacology 112 (1993) 121-128
6. Dekeyne A., and Millan M.J. Discriminative stimulus properties of antidepressant agents: a review. Behav. Pharmacol. 14 (2003) 391-407
7. Dekeyne A., Gobert A., Lob L., Cistarelli L., Melon C., and Millan M.C. Discriminative stimulus properties of the selective norephinephrine reuptake inhibitor, reboxetine in rats. Psychopharmacology 154 (2001) 213-218
8. Dekeyne A., Lob L., and Millan M.C. Following long-term training with citalopram both mirtazepine and mianserin block its discriminative stimulus properties in rats. Psychopharmacology 153 (2001) 389-392
9. Dziedzicka-Wasylewska M., Faron-Gorecka A., Kusmider M., Drozdowska E., Rogoz Z., Siwanowicz J., Caron M.G., and Bönisch H. Effect of antidepressant drugs in mice lacking the norepinephrine transporter. Neuropsychopharmacology 31 (2006) 2424-2432
10. Filip M., Chojnacka-Wojcik E., and Przegalinski E. Discriminative stimulus properties of (+)-oxaprotiline in rats. Pol. J. Pharmacol. 45 (1993) 151-154
11. Glennon R.A. Discriminative stimulus properties of hallucinogens and related designer drugs. In: Glennon R.A., Jarbe T.U.C., and Frankenheim J. (Eds). Drug Discrimination: Applications to Drug Abuse Research. NIDA Res. Monogr. (1991), NIDA, Rockville 25-45
12. Gommans J., Bouwknecht J.A., Hijzen T.H., Berendsen H.H., Broekkamp C.L., Maes R.A., and Olivier B. Stimulus properties of fluvaxamine in a conditioned taste aversion procedure. Psychopharmacology 140 (1998) 496-502
13. Goudie A.J., and Leathley M.J. Drug discrimination assays. In: Sahgal A. (Ed). Behavioural Neuroscience (1993), Oxford University Press, New York 145-167
14. Goudie A.J., and Smith J.A. Discriminative stimulus properties of antipsychotics. Pharmacol. Biochem. Behav. 64 (1999) 193-201
15. Grant V.L. Do conditioned taste aversions result from the activation of emetic mechanisms?. Psychopharmacology 93 (1987) 405-415
16. Harkin A.J., Bruce K.H., Craft B., and Paul I.A. Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 1. Acute treatments are active in the forced swim test. Eur. J. Pharmacol. 372 (1999) 207-213
17. Holliday S.M., and Benfield P. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs 49 (1995) 280-294
18. Kulkarni S.K., and Dhir A. Effect of various classes of antidepressants in behavioral paradigms of despair. Prog. Neuro-psychopharmacol. Biol. Psychiat. 31 (2007) 1248-1254
19. Llyod G.K., Cronin S., Fletcher A., and Mitchell P.J. The profile of venlafaxine, a novel antidepressant agent, in behavioral antidepressant drug models. Clin. Neuropharmacol. 15 (1992) 428B
20. Marona-Lewicka D., and Nichols D.E. Drug discrimination studies of the introceptive cues produced by selective serotonin uptake inhibitors and selective serotonin releasing agents. Psychopharmacology 138 (1998) 67-75
21. Mendlewicz J. Pharmacological profile and efficacy of venlafaxine. Int. Clin. Psychopharmacol. 10 Suppl 2 (1995) 5-13
22. Millan M.J., Gobert A., Girardon S., and Dekeyne A. Citalopram elicits a discriminative stimulus in rats at a dose selectively increasing extracellular levels of serotonin vs. dopamine and noradrenaline. Eur. J. Pharmacol. 364 (1999) 147-150
23. Olivier B., Bosch L., van Hest A., van der Heyden J., Mos J., van der Poel G., Schipper J., and Tulp M. Preclinical evidence on the psychotrophic profile of fluoxamine. Pharmacopsychiatry 26 (1993) 2-9
24. Page M.E., and Lucki E. Effects of acute and chronic reboxetine on stress-induced monoamine efflux in the rat frontal cortex. Neuropsychopharmacology 27 (2002) 237-247
25. Redrobe J.P., Bourin M., Colombel M.C., and Baker G.B. Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology 138 (1998) 1-8
26. Sánchez C., Bergqvist P.B., Brennum L.T., Gupta S., Hogg S., Larsen A., and Wiborg O. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology 167 (2003) 353-362
27. Shearman G., Miksic S., and Lal H. Discriminative stimulus properties of desipramine. Neuropharmacology 17 (1978) 1045-1048
28. Smith D., Dampster C., Glanville J., Freemantle N., and Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br. J. Psychiatry 180 (2002) 396-404
29. Thase M.E., Entsuah A.R., and Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 178 (2001) 234-241
30. Tran P.V., Bymaster F.P., McNamara R.K., and Potter W.Z. Dual monoamine modulation for improved treatment of major depressive disorder. J. Clin. Psychopharmacol. 23 (2003) 78-86
31. Wolf M.C., and Leander J.D. Discriminative stimulus properties of LW233708, a selective serotonin reuptake inhibitor in pigeon. Psychopharmacology 146 (1999) 275-279